[1] S.T. Anderson, J.D. Curlewis, PACAP stimulates dopamine neuronal
activity in the medial basal hypothalamus and inhibits prolactin,
Brain Res. 790 (1998) 343–346. [19]
[2] A. Arimura, Perspectives on pituitary adenylate cyclase activating
polypeptide (PACAP) in the neuroendocrine, endocrine, and nervous
systems, Jpn. J. Physiol. 48 (1998) 303–331. [20]
[3] R. Bals-Kubik, A. Ableitner, A. Herz, T.S. Shippenberg, Neuroanatomical sites mediating the motivational effects of opioids as
mapped by the conditioned place preference paradigm in rats, J.
Pharmacol. Exp. Ther. 264 (1993) 489–495. [21]
[4] J. Christophe, Type I receptors for PACAP (a neuropeptide even
more important than VIP?), Biochim. Biophys. Acta 1154 (1993) [22]
183–199.
[5] T.J. De Vries, A.N.M. Shoffelmeer, R. Binnekade, A.H. Mulder, [23]
L.J.M.J. Vanderschuren, Drug-induced reinstatement of heroin and
cocaine-seeking behaviour following long-term extinction is associ- [24]
ated with expression of behavioural sensitization, Eur. J. Neurosci.
10 (1998) 3565–3571.
[6] G. Di Chiara, A. Imperato, Drugs abused by humans preferentially
increase synaptic dopamine concentrations in the mesolimbic system
of freely moving rats, Proc. Natl. Acad. Sci. USA 85 (1988) [25]
5274–5278.
[7] T. Dickinson, S. Fleetwood-Walker, R. Mitchell, E.M. Lutz, Evidence for roles of vasoactive polypeptide (VIP) and pituitary
adenylate cyclase activating polypeptide (PACAP) receptors in [26]
